Skip to main content
Smart Investors Daily
Elutia Inc. logo

NASDAQ · ELUT

Elutia Inc.

Healthcare · Biotechnology

$0.81

Up+$0.09 (+11.12%)

Updated Nov 21, 2026, 1:34 AM

SID Score

3.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
29.77M
P/E ratio
-1.08
Dividend yield
0.00%
52-week range
$0.67 – $1.28
Volume
20.73K
Avg. volume
280.43K

Price performance · ELUT

ELUT price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 19, 2026

ELUT closed at $0.81 after 20 trading sessions, down 3.28% for the selected period.

Last close
$0.81
Period change
-3.28%
Period low
$0.75
Period high
$0.93
Daily close
View OHLC price history
ELUT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 19, 2026$0.8207$0.8384$0.8051$0.8120.73K
Nov 18, 2026$0.8593$0.8593$0.819$0.8314.52K
Nov 17, 2026$0.7982$0.9188$0.7982$0.853949.96K
Nov 16, 2026$0.8188$0.84$0.8008$0.822953.87K
Nov 13, 2026$0.8486$0.8799$0.7868$0.8250.44K
Nov 12, 2026$0.92$0.9399$0.8642$0.878883.19K
Nov 11, 2026$0.9192$0.9598$0.8934$0.9251.46K
Nov 10, 2026$0.83$0.95$0.82$0.9329298.46K
Nov 9, 2026$0.8534$0.88$0.83$0.835921.94K
Nov 6, 2026$0.7461$0.85$0.72$0.837485.11K
Nov 5, 2026$0.74$0.7967$0.7036$0.750987.54K
Nov 4, 2026$0.82$0.8233$0.75$0.759693.54K
Nov 3, 2026$0.82$0.8599$0.8113$0.813237.68K
Nov 2, 2026$0.8475$0.8598$0.8201$0.82134.65K
Oct 30, 2026$0.81$0.86$0.7992$0.8371138.31K
Oct 29, 2026$0.85$0.878$0.8002$0.813656.05K
Oct 28, 2026$0.802$0.84$0.802$0.83999.49K
Oct 27, 2026$0.83$0.86$0.802$0.804861.88K
Oct 26, 2026$0.811$0.8689$0.7676$0.798131K
Oct 23, 2026$0.879$0.8799$0.8086$0.837533.58K

Latest ELUT news

The latest Smart Investors Daily articles mentioning ELUT.

ELUT research

Overview

Company profile and research snapshot.

Company profile

Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$8.88
Implied upside
—
Analysts
—
ELUT recent ratings
DateFirmRatingTarget
Sep 10, 2025Lake StreetBuy—
May 9, 2025Lake StreetBuy—
Mar 7, 2025Cantor FitzgeraldOverweight—
Nov 15, 2024Cantor FitzgeraldOverweight—
Sep 6, 2024Cantor FitzgeraldOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 17, 2026

Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

GAITHERSBURG, Md., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a drug delivery company built to stop surgical infections, today announced that it granted equity awards on November 10, 2026 to two new employees as inducement awards under the Elutia Inc. 2026 Inducement Award Plan (the “Plan”). The awards were approved by the independent Compensation Committee of the Board of Directors and were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.